Human TIGIT (Luc) Jurkat Reporter Cell Development Service
描述（Description）
The Human TIGIT (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human TIGIT (Gene ID: 201633), which can use to evaluate the potency of TIGIT blockade. When co-cultured with target cells expressing human CD155, the TIGIT/CD155 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the TIGIT/CD155 interaction by either anti-TIGIT or anti-CD155 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.
應用說明（Application）
Screen for anti-human TIGIT or anti-human CD155 antibody.
生長特性（Growth Properties）
Suspension
篩選標記（Selection Marker）
Puromycin (5 μg/mL) + Hygromycin (20 μg/mL)
培養(yǎng)基（Culture Medium）
RPMI-1640 + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲（Storage）
Frozen in liquid nitrogen.
支原體檢測（Mycoplasma Testing）
Negative
無菌檢測（Sterility Testing）
Negative
使用說明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
T cell immunoglobulin and ITIM domain (TIGIT) is an immune checkpoint that has been considered as a target in cancer immunotherapy and belongs to the family of poliovirus receptors (PVRs) that competes against CD226 (DNAM-1), which is the co-stimulatory receptor of T cells and NK cells, by binding to CD112 and CD155 (PVR) that are expressed on antigen-presenting cells (APCs) and various non-hematopoietic cell types, such as tumor cells. The TIGIT/PVR axis imparts a co-inhibitory effect on both T and NK cells that lead to their exhaustion, in turn triggering a negative signal that suppresses their activities, resulting in tumor-immune evasion.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關鍵字： TIGIT報告細胞系;TIGIT細胞系;TIGIT細胞株;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。